FR2686899B1
(en)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
|
EP1037927B1
(en)
|
1997-12-08 |
2004-05-19 |
Lexigen Pharmaceuticals Corp. |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
ES2267263T3
(en)
*
|
1998-04-15 |
2007-03-01 |
Emd Lexigen Research Center Corp. |
COADMINISTRATION OF AN ANGIOGENESIS INHIBITOR TO REINFORCE THE IMMUNOLOGICAL RESPONSE THROUGH THE MEDIATION OF A FUSION PROTEIN OF A CYTOKIN WITH AN ANTIBODY.
|
US7304150B1
(en)
*
|
1998-10-23 |
2007-12-04 |
Amgen Inc. |
Methods and compositions for the prevention and treatment of anemia
|
AU773914B2
(en)
|
1999-02-01 |
2004-06-10 |
Eidgenossische Technische Hochschule Zurich |
Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
|
US6958212B1
(en)
|
1999-02-01 |
2005-10-25 |
Eidgenossische Technische Hochschule Zurich |
Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
|
US7345019B1
(en)
*
|
1999-04-13 |
2008-03-18 |
The Kenneth S. Warren Institute, Inc. |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
CZ299516B6
(en)
*
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
DK1200479T3
(en)
*
|
1999-08-09 |
2006-05-15 |
Emd Lexigen Res Ct Corp |
Multiple cytokine-antibody complexes
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
JP2003514552A
(en)
|
1999-11-12 |
2003-04-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
Erythropoietin morphology with improved properties
|
CA2399832C
(en)
|
2000-02-11 |
2011-09-20 |
Stephen D. Gillies |
Enhancing the circulating half-life of antibody-based fusion proteins
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
EP2267026A1
(en)
*
|
2000-04-12 |
2010-12-29 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1525889A1
(en)
*
|
2000-05-15 |
2005-04-27 |
F. Hoffmann-La Roche Ag |
Liquid pharmaceutical composition containing an erythropoietin derivative
|
ATE541587T1
(en)
*
|
2000-06-02 |
2012-02-15 |
Eidgenoess Tech Hochschule |
CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED RELEASE OF PHARMACEUTICALLY ACTIVE SUBSTANCES
|
US7291673B2
(en)
|
2000-06-02 |
2007-11-06 |
Eidgenossiche Technische Hochschule Zurich |
Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
|
DK1294401T3
(en)
*
|
2000-06-29 |
2007-10-08 |
Merck Patent Gmbh |
Improvement of antibody / cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake preparations
|
JP5170931B2
(en)
*
|
2000-10-16 |
2013-03-27 |
中外製薬株式会社 |
PEG-modified erythropoietin
|
EP1355965B1
(en)
|
2000-10-19 |
2012-09-19 |
Ecole Polytechnique Fédérale de Lausanne (EPFL) |
Method of synthesizing block copolymers for multifunctional self-assembled systems
|
KR101229995B1
(en)
*
|
2000-12-11 |
2013-02-06 |
씨제이 주식회사 |
Fusion protein having the enhanced in vivo activity of erythropoietin
|
WO2002048194A1
(en)
*
|
2000-12-11 |
2002-06-20 |
Cheil Jedang Corporation |
Fusion protein having the enhanced in vivo activity of erythropoietin
|
DE60144439D1
(en)
*
|
2000-12-20 |
2011-05-26 |
Hoffmann La Roche |
CONJUGATES OF ERYTHROPOIETIN (EPO) WITH POLYETHYLENE GLYCOL (PEG)
|
MXPA03005406A
(en)
|
2000-12-20 |
2003-09-25 |
Hoffmann La Roche |
Erythropoietin conjugates.
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
EP1234583A1
(en)
*
|
2001-02-23 |
2002-08-28 |
F. Hoffmann-La Roche Ag |
PEG-conjugates of HGF-NK4
|
AU2002248571B2
(en)
*
|
2001-03-07 |
2007-01-18 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
WO2002079415A2
(en)
*
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
BR0209177A
(en)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Recombinant tumor specific antibody and use
|
CA2446739A1
(en)
*
|
2001-05-25 |
2002-12-05 |
Human Genome Sciences, Inc. |
Chemokine beta-1 fusion proteins
|
US6930086B2
(en)
*
|
2001-09-25 |
2005-08-16 |
Hoffmann-La Roche Inc. |
Diglycosylated erythropoietin
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
WO2004099231A2
(en)
|
2003-04-09 |
2004-11-18 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
EP2279755B1
(en)
*
|
2001-10-10 |
2014-02-26 |
ratiopharm GmbH |
Remodelling and glycoconjugation of Fibroblast Growth Factor (FGF)
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7737260B2
(en)
*
|
2003-11-13 |
2010-06-15 |
Hanmi Pharm. Co., Ltd |
Protein complex using an immunoglobulin fragment and method for the preparation thereof
|
KR100467751B1
(en)
*
|
2001-12-03 |
2005-01-24 |
씨제이 주식회사 |
Fusion protein having the enhanced in vivo erythropoietin activity
|
EP2354791A1
(en)
*
|
2001-12-04 |
2011-08-10 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
KR100480423B1
(en)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
Conjugates of erythropoietin and polyethylene glycol derivatives
|
US20030176317A1
(en)
*
|
2001-12-06 |
2003-09-18 |
Volkmar Guenzler-Pukall |
Stabilization of hypoxia inducible factor (HIF) alpha
|
AU2002364587A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2003055526A2
(en)
*
|
2001-12-21 |
2003-07-10 |
Maxygen Aps |
Erythropoietin conjugates
|
PT1463751E
(en)
*
|
2001-12-21 |
2013-08-26 |
Human Genome Sciences Inc |
Albumin fusion proteins
|
US7300915B2
(en)
|
2002-06-05 |
2007-11-27 |
The Regents Of The University Of California |
Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
|
CA2493534C
(en)
*
|
2002-07-24 |
2010-01-26 |
Pascal Sebastian Bailon |
Pegylated t20 polypeptide
|
ATE344289T1
(en)
*
|
2002-07-24 |
2006-11-15 |
Hoffmann La Roche |
POLYETHYLENE GLYCOL ALDEHYDE DERIVATIVES
|
WO2004013165A1
(en)
*
|
2002-07-24 |
2004-02-12 |
F. Hoffmann-La Roche Ag |
Pegylated t1249 polypeptide
|
US7459435B2
(en)
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
ZA200505423B
(en)
*
|
2002-09-09 |
2008-08-27 |
Warren Pharmaceuticals Inc |
Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
|
US7459436B2
(en)
*
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
BRPI0317376B8
(en)
*
|
2002-12-17 |
2021-05-25 |
Merck Patent Gmbh |
antibody-il2 fusion protein designated as hu14.18-il2, uses thereof, vector and pharmaceutical composition
|
RS20050502A
(en)
*
|
2002-12-26 |
2007-08-03 |
Mountain View Pharmaceuticals Inc., |
Polymer conjugates of interferon- beta with enhanced biological potency
|
RS20050501A
(en)
*
|
2002-12-26 |
2007-08-03 |
Mountain View Pharmaceuticals Inc., |
Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
WO2004061094A1
(en)
*
|
2002-12-30 |
2004-07-22 |
Gryphon Therapeutics, Inc. |
Water-soluble thioester and selenoester compounds and methods for making and using the same
|
KR101031206B1
(en)
†
|
2002-12-31 |
2011-04-27 |
넥타르 테라퓨틱스 |
Maleamic acid polymer derivatives and their bioconjugates
|
JP4464395B2
(en)
*
|
2003-03-05 |
2010-05-19 |
ヘイローザイム インコーポレイテッド |
Soluble hyaluronidase glycoprotein (sHASEGP), process for its preparation, use and pharmaceutical composition comprising it
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
US7871607B2
(en)
*
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20050176108A1
(en)
*
|
2003-03-13 |
2005-08-11 |
Young-Min Kim |
Physiologically active polypeptide conjugate having prolonged in vivo half-life
|
US20040180054A1
(en)
*
|
2003-03-13 |
2004-09-16 |
Hanmi Pharm. Co., Ltd. |
Physiologically active polypeptide conjugate having prolonged in vivo half-life
|
BRPI0408358A
(en)
|
2003-03-14 |
2006-03-21 |
Neose Technologies Inc |
branched water-soluble polymers and their conjugates
|
EP1610825A2
(en)
*
|
2003-03-31 |
2006-01-04 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
WO2004101600A2
(en)
*
|
2003-05-12 |
2004-11-25 |
Affymax, Inc. |
Novel poly(ethylene glycol) modified compounds and uses thereof
|
ES2323465T3
(en)
*
|
2003-05-12 |
2009-07-16 |
Affymax, Inc. |
NOVELTY PEPTIDES THAT JOIN THE Erythropoietin Receptor.
|
MXPA05012314A
(en)
*
|
2003-05-12 |
2006-04-18 |
Affymax Inc |
Spacer moiety for poly(ethylene glycol) -modified peptides.
|
ES2395413T3
(en)
*
|
2003-05-12 |
2013-02-12 |
Affymax, Inc. |
Peptides that bind to the erythropoietin receptor
|
US7074755B2
(en)
*
|
2003-05-17 |
2006-07-11 |
Centocor, Inc. |
Erythropoietin conjugate compounds with extended half-lives
|
JP2007537986A
(en)
*
|
2003-05-30 |
2007-12-27 |
セントカー・インコーポレーテツド |
Formation of a novel erythropoietin complex using transglutaminase
|
EP1491554A1
(en)
*
|
2003-06-23 |
2004-12-29 |
CONARIS research institute AG |
PEGylated soluble gp130-dimers useful as a medicament
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
CN1882355A
(en)
*
|
2003-09-09 |
2006-12-20 |
沃伦药品公司 |
Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
|
CN1897959A
(en)
*
|
2003-09-29 |
2007-01-17 |
沃伦药品公司 |
Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
|
AU2004279895A1
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc |
Protein based TNF-alpha variants for the treatment of TNF-alpha related disorders
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
US7842661B2
(en)
|
2003-11-24 |
2010-11-30 |
Novo Nordisk A/S |
Glycopegylated erythropoietin formulations
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US20070254834A1
(en)
*
|
2003-11-24 |
2007-11-01 |
Defrees Shawn |
Glycopegylated Erythropoietin
|
US7956032B2
(en)
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
CA2549011A1
(en)
*
|
2003-12-10 |
2005-06-30 |
Nektar Therapeutics Al, Corporation |
Compositions comprising two different populations of polymer-active agent conjugates
|
ES2460671T3
(en)
*
|
2003-12-19 |
2014-05-14 |
F. Hoffmann-La Roche Ag |
Use of erythropoietin in the treatment of iron distribution disorders in chronic inflammatory bowel diseases
|
BRPI0418326A
(en)
|
2003-12-30 |
2007-05-02 |
Bionethos Holding Gmbh |
tissue regeneration method
|
AU2004309063B2
(en)
*
|
2003-12-31 |
2010-10-28 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
CA2552892C
(en)
|
2004-01-08 |
2014-08-05 |
Neose Technologies, Inc. |
O-linked glycosylation of peptides
|
CN1914223B
(en)
*
|
2004-02-02 |
2012-02-29 |
Ambrx公司 |
Modified human interferon polypeptides and their uses
|
US7588745B2
(en)
*
|
2004-04-13 |
2009-09-15 |
Si Options, Llc |
Silicon-containing products
|
US20080194475A1
(en)
*
|
2004-04-23 |
2008-08-14 |
Andrew Buchanan |
Erythropoietin Protein Variants
|
WO2006010143A2
(en)
|
2004-07-13 |
2006-01-26 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
|
US8268967B2
(en)
|
2004-09-10 |
2012-09-18 |
Novo Nordisk A/S |
Glycopegylated interferon α
|
EP1814573B1
(en)
|
2004-10-29 |
2016-03-09 |
ratiopharm GmbH |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
US7589063B2
(en)
*
|
2004-12-14 |
2009-09-15 |
Aplagen Gmbh |
Molecules which promote hematopoiesis
|
US20090118195A1
(en)
*
|
2004-11-10 |
2009-05-07 |
Hans-Georg Frank |
Molecules Which Promote Hematopoiesis
|
JP2008519858A
(en)
*
|
2004-11-11 |
2008-06-12 |
アフィーマックス・インコーポレイテッド |
A novel peptide that binds to the erythropoietin receptor
|
WO2006062685A2
(en)
*
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
ES2449195T3
(en)
*
|
2005-01-10 |
2014-03-18 |
Ratiopharm Gmbh |
Glycopegylated granulocyte colony stimulating factor
|
EP1848461A2
(en)
*
|
2005-02-16 |
2007-10-31 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
EP1871795A4
(en)
*
|
2005-04-08 |
2010-03-31 |
Biogenerix Ag |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
EP2377884A1
(en)
*
|
2005-05-10 |
2011-10-19 |
Neoloch Aps |
Neuritogenic peptides
|
US9988427B2
(en)
|
2005-05-13 |
2018-06-05 |
Charite Universitaetsmedizen-Berlin |
Erythropoietin variants
|
US20080255026A1
(en)
|
2005-05-25 |
2008-10-16 |
Glycopegylated Factor 1X |
Glycopegylated Factor Ix
|
US9505867B2
(en)
|
2005-05-31 |
2016-11-29 |
Ecole Polytechmique Fédérale De Lausanne |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7550433B2
(en)
*
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
CA2648732A1
(en)
*
|
2005-06-23 |
2006-12-28 |
Aplagen Gmbh |
Supravalent compounds
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
EP2380435B1
(en)
*
|
2005-08-31 |
2016-05-25 |
Kaneka Corporation |
Feline-derived erythropoietin and method for production thereof
|
JP5198747B2
(en)
*
|
2005-08-31 |
2013-05-15 |
株式会社カネカ |
Transgenic birds containing exogenous genes containing feline-derived protein coding sequences and methods for producing the same
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
AU2006304856A1
(en)
*
|
2005-10-21 |
2007-04-26 |
Synageva Biopharma Corp. |
Glycolated and glycosylated poultry derived therapeutic proteins
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
US20140113860A1
(en)
|
2006-02-03 |
2014-04-24 |
Prolor Biotech Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US10221228B2
(en)
|
2006-02-03 |
2019-03-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US9249407B2
(en)
|
2006-02-03 |
2016-02-02 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US8450269B2
(en)
|
2006-02-03 |
2013-05-28 |
Prolor Biotech Ltd. |
Long-acting growth hormone and methods of producing same
|
US10351615B2
(en)
|
2006-02-03 |
2019-07-16 |
Opko Biologics Ltd. |
Methods of treatment with long-acting growth hormone
|
US9458444B2
(en)
|
2006-02-03 |
2016-10-04 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US20150038413A1
(en)
|
2006-02-03 |
2015-02-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US7553941B2
(en)
|
2006-02-03 |
2009-06-30 |
Modigene Inc |
Long-acting polypeptides and methods of producing same
|
US8476234B2
(en)
*
|
2006-02-03 |
2013-07-02 |
Prolor Biotech Inc. |
Long-acting coagulation factors and methods of producing same
|
US8946155B2
(en)
|
2006-02-03 |
2015-02-03 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US8048848B2
(en)
|
2006-02-03 |
2011-11-01 |
Prolor Biotech Ltd. |
Long-acting interferons and derivatives thereof and methods thereof
|
US8759292B2
(en)
|
2006-02-03 |
2014-06-24 |
Prolor Biotech, Llc |
Long-acting coagulation factors and methods of producing same
|
US8304386B2
(en)
*
|
2006-02-03 |
2012-11-06 |
Prolor Biotech, Inc. |
Long-acting growth hormone and methods of producing same
|
US8048849B2
(en)
|
2006-02-03 |
2011-11-01 |
Modigene, Inc. |
Long-acting polypeptides and methods of producing same
|
CN101062407A
(en)
|
2006-04-29 |
2007-10-31 |
中国科学院上海生命科学研究院 |
Function of erythropoietin in the preventing and treating of retinal injury
|
CN101516388B
(en)
*
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
Glycosylation of peptides via O-linked glycosylation sequences
|
EP2054074B8
(en)
*
|
2006-08-04 |
2014-11-12 |
Prolong Pharmaceuticals, LLC |
Modified erythropoietin
|
WO2008057683A2
(en)
*
|
2006-10-03 |
2008-05-15 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
DK2068907T3
(en)
*
|
2006-10-04 |
2018-01-15 |
Novo Nordisk As |
GLYCEROL BOND PEGYLED SUGAR AND GLYCOPE Peptides
|
US20080083154A1
(en)
*
|
2006-10-05 |
2008-04-10 |
Timothy M Gregory |
Bait retention fish hook
|
WO2008057537A2
(en)
*
|
2006-11-08 |
2008-05-15 |
Maine Medical Center Research |
System and method for identifying erythropoietin-responsive genes
|
DK2081956T3
(en)
|
2006-11-13 |
2013-06-24 |
Charite Universitaetsmedizin |
METHOD OF CELL CULTIVATION AND METHOD OF TREATMENT INCLUDING A VEPO PROTEIN INVARIANT
|
KR20100016160A
(en)
|
2007-04-03 |
2010-02-12 |
바이오제너릭스 에이지 |
Methods of treatment using glycopegylated g-csf
|
WO2008154639A2
(en)
|
2007-06-12 |
2008-12-18 |
Neose Technologies, Inc. |
Improved process for the production of nucleotide sugars
|
EP2018835B1
(en)
|
2007-07-09 |
2014-03-05 |
Augustinus Bader |
Agent-eluting plaster
|
AR067536A1
(en)
|
2007-07-17 |
2009-10-14 |
Hoffmann La Roche |
METHOD FOR OBTAINING A MONO-PEGILATED ERYTHROPOYETIN IN A SUBSTANTIALLY HOMOGENOUS FORM
|
CL2008002053A1
(en)
|
2007-07-17 |
2009-05-22 |
Hoffmann La Roche |
Method for the purification of a monopeglated erythropoietin (epompeg) which consists of providing a solution containing mono, poly and non-peglated erythropoietin and passing it through two steps of cation exchange chromatography and a method to produce epo mpeg that includes a purification method.
|
CL2008002092A1
(en)
|
2007-07-20 |
2009-05-29 |
Hoffmann La Roche |
Conjugate containing two or more antifusogenic peptides and an anti-cd-4 antibody; Method of production; pharmaceutical composition comprising it; antifusogenic polypeptides and use of the conjugate to treat viral infections.
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
CN101381412B
(en)
*
|
2007-09-30 |
2012-02-22 |
深圳赛保尔生物药业有限公司 |
Polymer/recombinant human erythropoietin couple
|
CN101455844B
(en)
*
|
2007-12-10 |
2011-09-14 |
江苏豪森药业股份有限公司 |
PEG-erythrocyte-stimulating factor and preparation method and use thereof
|
CN102037004A
(en)
*
|
2008-01-08 |
2011-04-27 |
生物种属学股份公司 |
Glycoconjugation of polypeptides using oligosaccharyltransferases
|
DK3042922T3
(en)
|
2008-01-11 |
2017-10-23 |
Serina Therapeutics Inc |
MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COLPOLYMERS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME
|
US8101706B2
(en)
|
2008-01-11 |
2012-01-24 |
Serina Therapeutics, Inc. |
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
|
EP3103880A1
(en)
|
2008-02-08 |
2016-12-14 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
ES2476690T3
(en)
|
2008-02-27 |
2014-07-15 |
Novo Nordisk A/S |
Factor VIII conjugated molecules
|
TWI395593B
(en)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
In vivo temporal control of activatable matrix-degrading enzymes
|
EP2285402A2
(en)
|
2008-04-14 |
2011-02-23 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
TWI394580B
(en)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
Super fast-acting insulin compositions
|
ES2587400T3
(en)
|
2008-04-29 |
2016-10-24 |
Ascendis Pharma Growth Disorders Division A/S |
Pegylated recombinant human growth hormone compounds
|
EP2161031A1
(en)
|
2008-09-05 |
2010-03-10 |
SuppreMol GmbH |
Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
|
EP3216800A1
(en)
|
2008-09-26 |
2017-09-13 |
Ambrx, Inc. |
Modified animal erythropoietin polypeptides and their uses
|
WO2010068432A1
(en)
|
2008-11-25 |
2010-06-17 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Block copolymers and uses thereof
|
DK3037529T3
(en)
|
2008-12-09 |
2019-05-20 |
Halozyme Inc |
EXTENDED SOLUBLE PH20 POLYPEPTIDES AND USE THEREOF
|
GB0922354D0
(en)
|
2009-12-21 |
2010-02-03 |
Polytherics Ltd |
Novel polymer conjugates
|
MX347291B
(en)
|
2009-03-20 |
2017-04-17 |
Amgen Inc |
Carrier immunoglobulins and uses thereof.
|
US9663778B2
(en)
|
2009-07-09 |
2017-05-30 |
OPKO Biologies Ltd. |
Long-acting coagulation factors and methods of producing same
|
JP5734985B2
(en)
|
2009-09-17 |
2015-06-17 |
バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA |
Stable co-formulations of hyaluronidase and immunoglobulin and methods for their use
|
ES2632164T3
(en)
|
2010-07-06 |
2017-09-11 |
Augustinus Bader |
Topical application of erythropoietin for use in the treatment of corneal lesions
|
US9878046B2
(en)
|
2010-07-20 |
2018-01-30 |
Halozyme, Inc. |
Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
|
PL2616101T3
(en)
|
2010-09-14 |
2015-01-30 |
Hoffmann La Roche |
Method for purifying pegylated erythropoietin
|
EA201370076A1
(en)
|
2010-09-22 |
2013-08-30 |
Амген Инк. |
IMMUNE GLOBULIN TRANSFER AND THEIR APPLICATION
|
CN102453087B
(en)
*
|
2010-10-22 |
2013-12-25 |
广东赛保尔生物医药技术有限公司 |
Method for purification and preparation of mono-substituted PEG-EPO (polyethylene glycol-erythropoietin)
|
WO2012109387A1
(en)
|
2011-02-08 |
2012-08-16 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
CN103889443A
(en)
|
2011-06-17 |
2014-06-25 |
哈洛齐梅公司 |
Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
AU2012328880B2
(en)
|
2011-10-24 |
2017-02-23 |
Halozyme, Inc. |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
IL298330A
(en)
|
2011-12-30 |
2023-01-01 |
Halozyme Inc |
Ph20 polypeptide variants, formulations and uses thereof
|
EA031986B1
(en)
|
2012-04-04 |
2019-03-29 |
Галозим, Инк. |
Method and combination for treating solid tumor cancer and kit comprising the combination
|
JP2015520128A
(en)
|
2012-04-19 |
2015-07-16 |
オプコ バイオロジクス リミテッド |
Long-acting oxyntomodulin variants and methods for their preparation
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
KR102202255B1
(en)
|
2012-11-20 |
2021-01-13 |
옵코 바이오로직스 리미티드 |
Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
|
EP2740805B1
(en)
|
2012-12-07 |
2019-02-20 |
SuppreMol GmbH |
Stratification and treatment of patients suffering from idiopathic thrombocytopenic purpura
|
TW201534726A
(en)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
Thermally stable PH20 hyaluronidase variants and uses thereof
|
WO2015013510A1
(en)
|
2013-07-25 |
2015-01-29 |
Ecole Polytechnique Federale De Lausanne Epfl |
High aspect ratio nanofibril materials
|
US20150158926A1
(en)
|
2013-10-21 |
2015-06-11 |
Opko Biologics, Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
HUE043847T2
(en)
|
2014-08-28 |
2019-09-30 |
Halozyme Inc |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
EA201700181A1
(en)
|
2014-10-14 |
2017-09-29 |
Галозим, Инк. |
COMPOSITIONS OF ADENOSINDEMINASE-2 (ADA-2), THEIR OPTIONS AND METHODS OF USE
|
EP3220892B1
(en)
|
2014-11-21 |
2021-10-13 |
Ascendis Pharma Endocrinology Division A/S |
Long-acting growth hormone dosage forms
|
US10960058B2
(en)
|
2015-06-19 |
2021-03-30 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
AR107823A1
(en)
*
|
2016-03-07 |
2018-06-06 |
Hanmi Pharm Ind Co Ltd |
DERIVATIVES OF POLYETHYLENE GLYCOL AND USE OF THE SAME
|
CN105820232B
(en)
*
|
2016-04-08 |
2019-05-17 |
昂德生物药业有限公司 |
The preparation method and its product of mono-modified polyethylene glycol Recombinant Human Erythropoietin and application
|
CN118085104A
(en)
|
2016-07-11 |
2024-05-28 |
Opko生物科学有限公司 |
Long-acting coagulation factor and preparation method thereof
|
CN109415427A
(en)
|
2016-07-15 |
2019-03-01 |
豪夫迈·罗氏有限公司 |
Method for purifying the hematopoietin of Pegylation
|
US20190382462A1
(en)
|
2017-01-13 |
2019-12-19 |
Pietro P. Sanna |
Methods and compositions for treating hpa hyperactivity
|
KR102268647B1
(en)
|
2017-06-12 |
2021-06-23 |
한국코러스 주식회사 |
A Composition comprising erythropoietin and a method of producing the same
|
US10781435B2
(en)
|
2017-06-22 |
2020-09-22 |
Catalyst Biosciences, Inc. |
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
|
JP7227633B2
(en)
*
|
2017-12-29 |
2023-02-22 |
エフ. ホフマン-ラ ロシュ エージー. |
Methods for providing PEGylated protein compositions
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
EP3902913A1
(en)
|
2018-12-28 |
2021-11-03 |
Catalyst Biosciences, Inc. |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
CN111375068B
(en)
*
|
2018-12-29 |
2024-04-16 |
江苏豪森药业集团有限公司 |
Preparation method of polyethylene glycol polypeptide medicine
|
US20220387609A1
(en)
*
|
2019-03-29 |
2022-12-08 |
Nof Corporation |
Branched degradable polyethylene glycol binder
|
EP4219537A1
(en)
*
|
2020-09-22 |
2023-08-02 |
Jecho Laboratories, Inc. |
Glycosylation-modified erythopoietin and use thereof
|